Testing the accuracy of a four serum microRNA panel for the detection of primary bladder cancer: a discovery and validation study

References

• Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, Musolino C. 2012. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 41(6):1897–1912. doi: 10.3892/ijo.2012.1647
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, et al. 2021. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 81(1):75–94. doi: 10.1016/j.eururo.2021.08.010
   PubMed Web of Science ®Google Scholar
• Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. 2014. International variations in bladder cancer incidence and mortality. Eur Urol. 66(1):59–73. doi: 10.1016/j.eururo.2013.10.001
   PubMed Web of Science ®Google Scholar
• Cochetti G, Rossi de Vermandois JA, Maula V, Cari L, Cagnani R, Suvieri C, et al. 2022. Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial. Urol Oncol. 40:105 e11–e18.
   Web of Science ®Google Scholar
• Comperat EL, Roupret M, et al. 2015. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virch Arch. 466:589–594.
   PubMed Web of Science ®Google Scholar
• Dessie EY, Tsai JJP, Chang JG, Ng KL. 2021. A novel miRNA-based classification model of risks and stages for clear cell renal cell carcinoma patients. BMC Bioinformatics. 22(Suppl 10):270. doi: 10.1186/s12859-021-04189-2
   PubMed Web of Science ®Google Scholar
• Dp B. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Erdmann K, Salomo K, Klimova A, Heberling U, Lohse-Fischer A, Fuehrer R, et al. 2020. Urinary MicroRNAs as potential markers for non-invasive diagnosis of bladder cancer. Int J Mol Sci. 21(11):3814.
   Web of Science ®Google Scholar
• Feng Y, Liu J, Kang Y, He Y, Liang B, Yang P, Yu Z. 2014. miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. J Exp Clin Cancer Res. 33(1):67. doi: 10.1186/s13046-014-0067-8
   PubMedGoogle Scholar
• Frantzi M, Latosinska A, Flühe L, Hupe MC, Critselis E, Kramer MW, Merseburger AS, Mischak H, Vlahou A. 2015. Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol. 12(6):317–330. doi: 10.1038/nrurol.2015.100
   PubMed Web of Science ®Google Scholar
• Guo K, Qi D, Huang B. 2021. LncRNA MEG8 promotes NSCLC progression by modulating the miR-15a-5p-miR-15b-5p/PSAT1 axis. Cancer Cell Int. 21(1):84. doi: 10.1186/s12935-021-01772-8
   PubMed Web of Science ®Google Scholar
• Han J, Wang J-Z, Yang X, Yu H, Zhou R, Lu H-C, Yuan W-B, Lu J-C, Zhou Z-J, Lu Q, et al. 2019. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer. 18(1):110. doi: 10.1186/s12943-019-1036-9
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer. 2021. Estimated number of new cases in 2020, worldwide, both sexes, all ages. Geneva, Switzerland: World Health Organization.
   Google Scholar
• Krajewski W, Kościelska-Kasprzak K, Rymaszewska J, Zdrojowy R. 2017. How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial. Qual Life Res. 26(3):625–634. doi: 10.1007/s11136-016-1493-1
   PubMed Web of Science ®Google Scholar
• Lee YS. 2009. DA. MicroRNAs in cancer. Annu Rev Pathol. 4:199–227.
   PubMed Web of Science ®Google Scholar
• Lenis AT, Lec PM, Chamie K, Mshs MD. 2020. Bladder cancer: a review. JAMA. 324(19):1980–1991. doi: 10.1001/jama.2020.17598
   PubMed Web of Science ®Google Scholar
• Lin JT, Tsai KW. 2021. Circulating miRNAs act as diagnostic biomarkers for bladder cancer in urine. Int J Mol Sci. 22(8):4278. doi: 10.3390/ijms22084278
   Web of Science ®Google Scholar
• Liu X, Zhou Z, Wang Y, Zhu K, Deng W, Li Y, Zhou X, Chen L, Li Y, Xie A, et al. 2020. Downregulation of HMGA1 mediates autophagy and inhibits migration and invasion in bladder cancer via miRNA-221/TP53INP1/p-ERK Axis. Front Oncol. 10:589. doi: 10.3389/fonc.2020.00589
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25(4):402–408. doi: 10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• Lu J, Li S, Li X, Zhao W, Duan X, Gu X, Xu J, Yu B, Sigal LJ, Dong Z, et al. 2021. Declined miR-181a-5p expression is associated with impaired natural killer cell development and function with aging. Aging Cell. 20(5):e13353. doi: 10.1111/acel.13353
   PubMed Web of Science ®Google Scholar
• Mao W, Huang X, Wang L, Zhang Z, Liu M, Li Y, Luo M, Yao X, Fan J, Geng J, et al. 2019. Circular RNA hsa_circ_0068871 regulates FGFR3 expression and activates STAT3 by targeting miR-181a-5p to promote bladder cancer progression. J Exp Clin Cancer Res. 38(1):169. doi: 10.1186/s13046-019-1136-9
   PubMedGoogle Scholar
• Ng K, Stenzl A, Sharma A, Vasdev N. 2021. Urinary biomarkers in bladder cancer: a review of the current landscape and future directions. Urol Oncol. 39(1):41–51. doi: 10.1016/j.urolonc.2020.08.016
   PubMed Web of Science ®Google Scholar
• Piao XM, Cha EJ, Yun SJ, Kim WJ. 2021. Role of exosomal miRNA in bladder cancer: a promising liquid biopsy biomarker. Int J Mol Sci. 22(4):1713. doi: 10.3390/ijms22041713
   PubMed Web of Science ®Google Scholar
• Poli G, Egidi MG, Cochetti G, Brancorsini S, Mearini E. 2020. Relationship between cellular and exosomal miRNAs targeting NOD-like receptors in bladder cancer: preliminary results. Minerva Urol Nefrol. 72(2):207–213. doi: 10.23736/S0393-2249.19.03297-1
   PubMed Web of Science ®Google Scholar
• Su S-F, Chang Y-W, Andreu-Vieyra C, Fang JY, Yang Z, Han B, Lee AS, Liang G. 2013. miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene. 32(39):4694–4701. doi: 10.1038/onc.2012.483
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. 2017. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45(W1):W98–W102. doi: 10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. 2021. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 21(2):104–121. doi: 10.1038/s41568-020-00313-1
   PubMed Web of Science ®Google Scholar
• Tsikrika FD, Avgeris M, Levis PK, Tokas T, Stravodimos K, Scorilas A. 2018. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients’ risk for short-term relapse and progression. Genes Chromosomes Cancer. 57(3):150–161. doi: 10.1002/gcc.22516
   PubMed Web of Science ®Google Scholar
• Valenberg F, Ha WE, et al. 2019. Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer. Eur Urol. 75:853–860.
   PubMed Web of Science ®Google Scholar
• van der Aa MNM, Steyerberg EW, Bangma C, van Rhijn BWG, Zwarthoff EC, van der Kwast TH. 2010. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial. J Urol. 183(1):76–80. doi: 10.1016/j.juro.2009.08.150
   PubMed Web of Science ®Google Scholar
• Wu H, Tian X, Zhu C. 2020. Knockdown of lncRNA PVT1 inhibits prostate cancer progression in vitro and in vivo by the suppression of KIF23 through stimulating miR-15a-5p. Cancer Cell Int. 20(1):283. doi: 10.1186/s12935-020-01363-z
   PubMed Web of Science ®Google Scholar
• Xie Y, Ma X, Chen L, Li H, Gu L, Gao Y, Zhang Y, Li X, Fan Y, Chen J, et al. 2017. MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis. Sci Rep. 7(1):5619. doi: 10.1038/s41598-017-05801-3
   PubMedGoogle Scholar
• Zeng LP, Hu ZM, Li K, Xia K. 2016. miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells. J Cell Mol Med. 20:559–567.
   PubMed Web of Science ®Google Scholar
• Zhang DQ, Zhou CK, Jiang XW, Chen J, Shi BK. 2014. Increased expression of miR-222 is associated with poor prognosis in bladder cancer. World J Surg Oncol. 12(1):241. doi: 10.1186/1477-7819-12-241
   PubMedGoogle Scholar
• Zhang Y, Luo G, You S, Zhang L, Liang C, Chen X. 2021. Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell proliferation and invasion by regulating miR-15a-5p/HMGA2 axis. Acta Biochim Biophys Sin. 53:673–682.
   Google Scholar